According to the European Society for Medical Oncology (ESMO) pan‐Asia guidelines for the management of NSCLC, patients with tumours harbouring a sensitizing EGFR mutation should receive any first‐line EGFR TKIs, including osimertinib, erlotinib, gefitinib, or afatinib, and for those experiencing disease progression, osimertinib is recommended following a liquid biopsy or tissue rebiopsy in those with acquired T790M mutation.8 This evidence concerns the gene EGFR and non-small cell lung carcinoma.